Clinical data | |
---|---|
Pronunciation | bep oh tas' teen |
Trade names | Bepreve[1] |
Other names | Bepotastine besilate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610012 |
Routes of administration | By mouth, eye drops |
Drug class | Antihistamine, hay fever, hives[2][1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High (by mouth) Minimal (topical) |
Protein binding | ~55% |
Excretion | Renal (75–85 |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H25ClN2O3 |
Molar mass | 388.89 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Bepotastine, sold under the brand names Bepreve among others, is a medication used as an eye drop to treat allergic conjunctivitis.[1] By mouth it may be used for allergic rhinitis (hay fever) and hives.[2]
Common side effects eye irritation, headache, and stuffy nose.[3] While there is no evidence of harm in pregnancy, such use has not been well studied.[3][4] It is an antihistamine and mast cell stabilizer.[1]
Bepotastine was approved for medical use in Japan in 2000 and the United States in 2009.[2][3] In the United States 5 ml for the eyes costs about 70 USD as of 2022.[5]
References
edit- ^ a b c d e "Bepotastine Monograph for Professionals". Drugs.com. Archived from the original on 27 October 2021. Retrieved 24 November 2021.
- ^ a b c Leung, Donald Y. M.; Sampson, Hugh; Geha, Raif; Szefler, Stanley J. (13 October 2010). Pediatric Allergy: Principles and Practice E-Book. Elsevier Health Sciences. ISBN 978-1-4377-3778-3. Archived from the original on 11 January 2022. Retrieved 9 January 2022.
- ^ a b c d "DailyMed - BEPOTASTINE BESILATE solution/ drops". dailymed.nlm.nih.gov. Archived from the original on 11 January 2022. Retrieved 9 January 2022.
- ^ "Bepotastine ophthalmic (Bepreve) Use During Pregnancy". Drugs.com. Archived from the original on 25 October 2021. Retrieved 9 January 2022.
- ^ "Bepotastine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 23 August 2016. Retrieved 9 January 2022.